Vmbook Online ordering

Ocera Therapeutics Inc

Ocera Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics designed to restore balance to the gut-liver axis for patients with serious liver diseases. The company's lead product candidate was OCR-002 (aka galactose-based sodium galactose sulfate), an experimental oral, gut-targeted therapy for the prevention and treatment of hepatic encephalopathy (HE) in patients with liver cirrhosis.

Unfortunately, the company has faced significant challenges in its clinical development and financial position in recent years. On December 10, 2018, Ocera announced that it had entered into an Agreement and Plan of Merger with Frazier Healthcare Partners, whereby Frazier Acquisition Sub, Inc., a newly formed subsidiary of Frazier Healthcare Partners, would acquire Ocera. As a result of the merger, Ocera Therapeutics, Inc. ceased to exist as an independent, publicly traded entity, and the company's common stock was delisted from the Nasdaq Stock Market.